S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
S&P 500   3,941.26
DOW   33,596.34
QQQ   281.68
Franchising Could Be the Secret to Reaping the Rewards of a Down Economy. Here Are 5 Reasons Why.
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Splunk is Suddenly Looking Like a Slam Dunk
3 Big Box Retail Bets for the Holidays
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
How Long Does it Take to Become a Profitable Trader?
Biden visits Arizona computer chip site, highlights jobs
China Threatens U.S. Defense and Economic Security (Ad)
Is Autozone Ready To Rally For Another Profitable Lap?
Trump Org. jury seeks clarity as deliberations continue
NASDAQ:VTGN

VistaGen Therapeutics - VTGN Stock Forecast, Price & News

$0.13
+0.01 (+8.25%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.13
▼
$0.17
50-Day Range
$0.10
▼
$0.16
52-Week Range
$0.08
▼
$2.11
Volume
44.13 million shs
Average Volume
5.80 million shs
Market Capitalization
$27.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VistaGen Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-1.53mentions of VistaGen Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.28) to ($0.19) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.33 out of 5 stars

See Top Rated MarketRank™ Stocks Here
VTGN stock logo

About VistaGen Therapeutics (NASDAQ:VTGN) Stock

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

December 6, 2022 | marketwatch.com
Vistagen Therapeutics Shares Rise on FDA Fast-Track Designation >VTGN
December 6, 2022 | finance.yahoo.com
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
November 30, 2022 | finance.yahoo.com
Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 17, 2022 | finance.yahoo.com
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
November 15, 2022 | finance.yahoo.com
What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
November 10, 2022 | finance.yahoo.com
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
November 9, 2022 | msn.com
Earnings Outlook For VistaGen Therapeutics
November 4, 2022 | finance.yahoo.com
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 3, 2022 | finance.yahoo.com
Vistagen to Present at Stifel 2022 Healthcare Conference
October 26, 2022 | finance.yahoo.com
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
October 22, 2022 | finance.yahoo.com
Shareholders Will Likely Find VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) CEO Compensation Acceptable
October 19, 2022 | finance.yahoo.com
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
October 6, 2022 | finance.yahoo.com
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote "FOR" Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
October 5, 2022 | marketwatch.com
InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Participate at Cantor Neurology & Psychiatry Conference
October 3, 2022 | finance.yahoo.com
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
September 24, 2022 | finance.yahoo.com
Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m
September 20, 2022 | finance.yahoo.com
Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
September 19, 2022 | finance.yahoo.com
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
September 9, 2022 | finance.yahoo.com
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
September 8, 2022 | finance.yahoo.com
Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial
September 8, 2022 | finance.yahoo.com
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
September 6, 2022 | finance.yahoo.com
VistaGen Therapeutics, Inc. (VTGN)
August 12, 2022 | seekingalpha.com
VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss
August 12, 2022 | seekingalpha.com
VistaGen Therapeutics, Inc.'s (VTGN) CEO Shawn Singh on Q1 2023 Results -Earnings Call Transcript
August 11, 2022 | finance.yahoo.com
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
See More Headlines
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Company Calendar

Last Earnings
11/10/2021
Today
12/06/2022
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
CUSIP
N/A
CIK
1411685
Web
www.vistagen.com
Phone
(650) 577-3600
Fax
888-482-2602
Employees
31
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-47,760,000.00
Net Margins
-5,614.37%
Pretax Margin
-5,613.99%
Return on Equity
-117.05%
Return on Assets
-97.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.11
Quick Ratio
6.11

Sales & Book Value

Annual Sales
$1.11 million
Price / Sales
24.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
206,836,000
Free Float
198,542,000
Market Cap
$27.14 million
Optionable
Not Optionable
Beta
0.50

Key Executives

  • Mr. Shawn K. Singh J.D. (Age 59)
    CEO & Director
    Comp: $912.5k
  • Mr. Jerrold D. Dotson CPA (Age 69)
    CPA, CFO, VP & Sec.
    Comp: $577.5k
  • Mr. Reid G. Adler Esq. (Age 68)
    J.D., Chief Legal Officer
  • Dr. Mark A. Smith M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $658.75k
  • Ms. Ann Michelle Cunningham M.B.A. (Age 54)
    Chief Commercial Officer & Director
    Comp: $576.44k
  • Mr. Mark Flather
    VP of Investor Relations
  • Mr. Mark Adrian McPartland (Age 56)
    VP of Corp. Devel.
  • Ms. Trisha Fitzmaurice
    VP of HR
  • Dr. Allen Easley Cato III
    M.D., Ph.D., Sr. VP of Devel. Operations
  • Dr. Mark J. Ginski (Age 50)
    Sr. VP and Head of Chemistry, Manufacturing & Controls

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VTGN Stock - Frequently Asked Questions

Should I buy or sell VistaGen Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares.
View VTGN analyst ratings or view top-rated stocks.

How have VTGN shares performed in 2022?

VistaGen Therapeutics' stock was trading at $1.95 at the beginning of 2022. Since then, VTGN shares have decreased by 93.2% and is now trading at $0.1324.
View the best growth stocks for 2022 here.

When is VistaGen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our VTGN earnings forecast.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $0.36 million for the quarter, compared to analysts' expectations of $0.33 million. VistaGen Therapeutics had a negative net margin of 5,614.37% and a negative trailing twelve-month return on equity of 117.05%. During the same period in the previous year, the firm posted ($0.05) EPS.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (2.72%), Vanguard Group Inc. (2.29%), Renaissance Technologies LLC (1.82%), Two Sigma Investments LP (0.41%), Bank of New York Mellon Corp (0.28%) and Two Sigma Advisers LP (0.11%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.13.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $27.39 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.

This page (NASDAQ:VTGN) was last updated on 12/7/2022 by MarketBeat.com Staff